Systemic Anti-Cancer Therapy Regimen Library
MPN - busulfan
Treatment Overview
Repeat cycles depending on clinical response.
Frequency of cycles can be variable and can be repeated once every 28 to 90 days depending on clinical response and patient factors.
An alternative dosing regimen of busulfan 20 mg orally as a single dose may be appropriate for patients requiring treatment under supervision.
Cycle 1 (and all further cycles) - 28 days
Cycle details
Cycle 1 (and all further cycles) - 28 days
| Medication | Dose | Route | Days | Max Duration |
|---|---|---|---|---|
| busulfan | 4 mg flat dosing Once daily | oral administration | 1 to 7 |
Full details
Cycle 1 (and all further cycles) - 28 days
Day: 1
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| busulfan | 4 mg flat dosing Once daily | oral administration |
Instructions:
Take with food. |
Day: 2
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| busulfan | 4 mg flat dosing Once daily | oral administration |
Instructions:
Take with food. |
Day: 3
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| busulfan | 4 mg flat dosing Once daily | oral administration |
Instructions:
Take with food. |
Day: 4
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| busulfan | 4 mg flat dosing Once daily | oral administration |
Instructions:
Take with food. |
Day: 5
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| busulfan | 4 mg flat dosing Once daily | oral administration |
Instructions:
Take with food. |
Day: 6
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| busulfan | 4 mg flat dosing Once daily | oral administration |
Instructions:
Take with food. |
Day: 7
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| busulfan | 4 mg flat dosing Once daily | oral administration |
Instructions:
Take with food. |
Supportive Care Factors
| Factor | Value |
|---|---|
| Emetogenicity: | Medium to high |
| Tumour lysis syndrome prophylaxis: | Tumour lysis syndrome prophylaxis may be considered |
Antiviral prophylaxis for hepatitis B virus: Guidance is limited to high-risk anti-cancer medicines. Clinicians will need to assess individual patient risk for other anti-cancer medicines.
References
Pharmacy Retailing PTY Ltd Myleran New Zealand Data Sheet 16 September 2020 https://www.medsafe.govt.nz/profs/datasheet/m/Mylerantab.pdf (accessed 21 January 2022).
NHS Thames Valley Strategic Clinical Network Busulfan October 2019 http://www.nssg.oxford-haematology.org.uk/myeloid/protocols/ML-42-busulfan.pdf (accessed 21 January 2022).
* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.
s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.